InVentis Technologies to Distribute TriLink Products in India
News Nov 07, 2014
TriLink BioTechnologies, Inc. has entered into a distribution agreement with inVentis Technologies, an Indian distribution and manufacturing company specializing in the life science and applied science, research, diagnostics and QC market. The agreement allows inVentis to market TriLink’s complete line of nucleic acid-based products. This includes TriLink’s stocked and custom nucleotides, oligonucleotides and mRNA, as well as their CleanAmp™ Hot Start PCR Products.
"With the biotech industry growing rapidly in India, TriLink has been looking for the right opportunity to enter the market. InVentis provides an extensive line of life science products to the biotech and pharmaceutical market and we feel that our high quality nucleic acid-based products will complement their offering and help advance research in the area,” commented TriLink's President and CEO, Richard Hogrefe, Ph.D.
“With the biotechnology industry in India increasingly focused on “OMICS”, InVentis has been looking for a world-class nucleic acid-based product line to fulfill the growing demand in the genomics and molecular biology sector. We anticipate that the market will continue to grow and addition of TriLink products will complement the portfolio offered by InVentis”, stated Founder and BM Singh, Sandeep. “We are delighted to enter into an agreement with TriLink.”
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019